Neogenomics, Inc.
NEO
$7.88
-$0.10-1.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 190.17M | 187.80M | 181.33M | 168.04M | 172.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 190.17M | 187.80M | 181.33M | 168.04M | 172.00M |
| Cost of Revenue | 106.83M | 107.35M | 104.47M | 94.79M | 94.74M |
| Gross Profit | 83.34M | 80.45M | 76.86M | 73.25M | 77.26M |
| SG&A Expenses | 86.65M | 86.95M | 91.36M | 87.91M | 84.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 202.65M | 202.99M | 204.86M | 192.88M | 187.30M |
| Operating Income | -12.48M | -15.19M | -23.53M | -24.84M | -15.30M |
| Income Before Tax | -12.41M | -26.39M | -45.82M | -25.66M | -16.13M |
| Income Tax Expenses | -2.53M | 740.00K | -724.00K | 266.00K | -804.00K |
| Earnings from Continuing Operations | -9.88M | -27.13M | -45.09M | -25.92M | -15.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.88M | -27.13M | -45.09M | -25.92M | -15.32M |
| EBIT | -12.48M | -15.19M | -23.53M | -24.84M | -15.30M |
| EBITDA | 3.91M | 1.24M | -6.26M | -7.11M | 2.89M |
| EPS Basic | -0.08 | -0.21 | -0.35 | -0.20 | -0.12 |
| Normalized Basic EPS | -0.06 | -0.07 | -0.11 | -0.11 | -0.06 |
| EPS Diluted | -0.08 | -0.21 | -0.35 | -0.20 | -0.12 |
| Normalized Diluted EPS | -0.06 | -0.07 | -0.11 | -0.11 | -0.06 |
| Average Basic Shares Outstanding | 128.65M | 128.42M | 127.95M | 127.38M | 127.16M |
| Average Diluted Shares Outstanding | 128.65M | 128.42M | 127.95M | 127.38M | 127.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |